Multicomponent and regioselective synthesis of dihydropyrazolo[1,5-a]pyrimidines from aromatic aldehydes, Meldrum's acid and aminopyrazole CAN508

Article abstract of DOI:10.3987/COM-14-13026

A regioselective synthesis of dihydropyrazolo[1,5-a]pyrimidines is reported. The multicomponent reaction of readily available arylaldehydes, Meldrum's acid, and aminopyrazole CAN508 afforded fused pyrazolopyrimidines in high yields. The reaction proceeded regioselectively via initial Michael addition of the exocyclic amino group to arylidene Meldrum's acid intermediate followed by a ring closure at the endocyclic nitrogen of aminopyrazole. The regioselectivity of the reaction was determined by X-ray crystallography.

Full text of DOI:10.3987/COM-14-13026

1892
HETEROCYCLES, Vol. 89, No. 8, 2014
HETEROCYCLES, Vol. 89, No. 8, 2014, pp. 1892 - 1904. © 2014 The Japan Institute of Heterocyclic Chemistry
Received, 14th May, 2014, Accepted, 29th May, 2014, Published online, 16th June, 2014
DOI: 10.3987/COM-14-13026
MULTICOMPONENT AND REGIOSELECTIVE SYNTHESIS OF
DIHYDROPYRAZOLO[1,5-a]PYRIMIDINES
FROM
AROMATIC
ALDEHYDES, MELDRUM´S ACID AND AMINOPYRAZOLE CAN508
Lukáš Jedinák,a Vladimír Kryštof,b Zdeněk Trávníček,c and Petr Cankařa*
aDepartment of Organic Chemistry, Faculty of Science, Palacky University, 17.
listopadu
1192/12,
77146
Olomouc,
Czech
Republic.
E-mail:
cankar@orgchem.upol.cz, Tel: +420585634437, Fax: +420585634465
bLaboratory of Growth Regulators, Centre of the Region Hana for
Biotechnological and Agricultural Research, Institute of Experimental Botany
ASCR &Palacky University, Slechtitelů 11, 783 71 Olomouc, Czech Republic
cRegional Centre of Advanced Technologies and Materials, Department of
Inorganic Chemistry, Faculty of Science, Palacky University, 17. Listopadu
1192/12, 77146 Olomouc, Czech Republic
Abstract – A regioselective synthesis of dihydropyrazolo[1,5-a]pyrimidines is
reported. The multicomponent reaction of readily available arylaldehydes,
Meldrum´s acid, and aminopyrazole CAN508 afforded fused pyrazolopyrimidines
in high yields. The reaction proceeded regioselectively via initial Michael addition
of the exocyclic amino group to arylidene Meldrum´s acid intermediate followed
by a ring closure at the endocyclic nitrogen of aminopyrazole. The regioselectivity
of the reaction was determined by X-ray crystallography.
Pyrazolopyrimidines belong to a class of fused heterocyclic compounds, which have found a broad
application in the field of medicinal chemistry. Structures containing pyrazolo[1,5-a]pyrimidine core have
been reported as antitrichomonal agents,1 cAMPphosphodiesterase inhibitors,2 selective COX-2
inhibitors,3 benzodiazepine receptor antagonists,4 CRF receptor antagonists,5 and estrogen receptor
antagonists.6 Structural similarity to purine bases makes them a suitable scaffold for the development of
competitive inhibitors of therapeutically useful protein kinases including c-SRC,7 Jak2,8 PI3Kβ,9 and
cyclin-dependent kinases.10 Partially saturated analogues of dihydropyrazolo[1,5-a]pyrimidines are also
structures of interest from the biological point of view. Recently, they were identified as potent

HETEROCYCLES, Vol. 89, No. 8, 2014
1893
antagonists of potassium channel and the most promising compound entered clinical trials for the
treatment of atrial fibrillation.11
In general, dihydropyrazolo[1,5-a]pyrimidines could be prepared either using sequential protocol starting
with the synthesis of the ,-unsaturated carbonyl compound, followed by cyclocondensation with
3(5)-aminopyrazole,12 or in one-step via multicomponent Biginelli type reaction of aldehyde,
1,3-dicarbonyl compound and aminopyrazole.13
Multicomponent reactions (MCRs) have received appreciable attention from the organic chemists due to
several advantages over conventional multistep synthesis, since they provide rapid and effective
generation of libraries of heterocyclic compounds with varied substitution patterns. In addition, MCRs are
more often atom economic and ecologically benign as they avoid time-consuming and expensive
purification processes, as well as protection and deprotection steps.14 Among numerous MCRs known, a
tandem of Knoevenagel condensation and Michael addition transformations utilizing Meldrum´s acid as a
C2 synthon represent an outstanding instrument for the synthesis of heterocycles.15 For instance, the
MCRs involving Meldrum´s acid have been reported in the synthesis of pyridine,16a pyrimidine,16b
quinoline,16c and spiroindole.16d
In the course of research program towards the development of synthetic inhibitors of cyclin-dependent
kinases (CDKs), aminopyrazole (CAN508,compound 1) was identified as a potent and selective CDK
inhibitor with preference to CDK9.17 Moreover, compound (1) showed antiproliferative activity on
several cancer cell lines. In addition, it was found that the introduction of an acyl substituent at the
exocyclic amino group increased the potency against CDK2.17b
This finding encouraged us to further modify the aminopyrazole core of compound (1). Since some
pyrazolopyrimidines are known inhibitors of CDKs and structure (1) is appropriate starting material in the
synthesis of fused pyrazolopyrimidines, as it contains amidine-like 1,3-bisnucleophilic scaffold, we
developed an efficient MCR of aminopyrazole (1), Meldrum´s acid (2) and arylaldehydes (3), leading to
pyrazolo[1,5-a]pyrimidines (4) (Scheme 1).
Scheme 1

1894
HETEROCYCLES, Vol. 89, No. 8, 2014
Initially, we started with the synthesis of pyrazolopyrimidne (4a) by the cyclocondensation of
commercially available cinnamate (5) with aminopyrazole (1) (Scheme 2). In general, the reaction of
,-unsaturated esters with aminoazoles are known to proceed at high temperatures and usually in lower
yields.12a,b In our case, the cyclocondensation was examined at various conditions using conventional
heating or microwave irradiation, acid (HCl, ZnCl2) or base (Et3N, DBU, NaOH) catalysis, but the
desired product was not obtained. Only traces of compound (4a) were detected by HPLC-MS in the crude
reaction mixture, while the starting materials, ester (5) and pyrazole (1), remained almost unreacted.
These results indicated, that conjugation of the C=C bond with one ester group is insufficient to allow
Michael addition of aminopyrazole (1).
Scheme 2. Conditions: a) 20 mol% ZnCl2 or HCl, MeOH, reflux/MW; b) 10 - 20 mol% DBU or NaOH,
MeOH reflux/MW.
In order to increase electrophilicity of the C=C bond it was introduced a second ester group in a form of
arylidene Meldrum´s acids. Subsequently, preliminary experiments were focused on the MCR of
aminopyrazole (1), Meldrum´s acid (2), and 4-methoxybenzaldehyde (3a), Table 1 (Scheme 1, R =
4-OMe). All three components were stirred in EtOH at room temperature and the desired product (4a)
was isolated by filtration in 52% yield (Entry 1). The mother liquor contained small amount of (4a)
together with unreacted pyrazole (1) (recovered 23%) and arylidene Meldrum´s acid (6). When the MCR
was performed in the presence of a catalytic amount of base, the isolated yield of (4a) slightly increased,
but the reaction was not complete even after 16 hours (Entries 2, 3, and 4). Attempts to promote the
reaction with acid failed, since the addition of 10 mol% of ZnCl2 or HCl led to lower isolated yields
(Entries 5 and 6). A full conversion of starting aminopyrazole (1) was achieved, when the reaction was
carried out in boiling EtOH without addition of any catalyst (Entry 7).
These results indicated that the MCR can be promoted with a base, the catalyst is not necessary, and the
high isolated yield can be reached at slightly elevated temperature (~ 80 °C). Other solvents, MeCN, THF,
AcOH and pyridine, were also examined. The reaction in boiling pyridine gave comparable result to

HETEROCYCLES, Vol. 89, No. 8, 2014
1895
EtOH (Entry 11), while MeCN and THF provided (4a) in lower yields (Entries 8 and 9). The complex
mixture was obtained, when AcOH was used as a solvent, and only traces of (4a) were detected by
HPLC-MS. Since the reaction in boiling EtOH without any catalyst gave the highest isolated yield (Entry
7), these conditions were used for the synthesis of pyrazolopyrimidines (4a-q).
Table 1. The optimisation of MCR of pyrazole (1), Medldrum´s acid (2)
and 4-methoxybenzaldehyde (3a)
Entry Solvent
Catalyst
T (°C)
Yielda (%)
(20 mol%)
1
2
EtOH
EtOH
EtOH
EtOH
EtOH
EtOH
EtOH
MeCN
THF
-
rt
rt
52
63
71
64
42
49
86
37
32
-
Et3N
3
DBU
rt
4
NaOH
rt
5
ZnCl2
rt
6
HCl
rt
7
-
-
-
-
-
reflux
reflux
reflux
reflux
reflux
8
9
10
11
AcOH
pyridine
77
aIsolated yield of pyrazolopyrimidine (4a) after 16 hours.
OMe
O
N
N
N
N
NH2
NH2
N
H
O
N
H
N
N
N
N
MeO
OH
4a
4a´
OH
Figure 1.Regioisomeric structures (4a) and (4a´). X-Ray structure of (4a); ellipsoids are drawn at the
40% probability level. Only one of two crystallographically independent molecules is shown, the second
part of the disordered C5H moiety is omitted for clarity.

1896
HETEROCYCLES, Vol. 89, No. 8, 2014
It should be noted, that the compound (4a) was isolated as the single regioisomer. Theoretically, the MCR
depicted in Scheme 1 could provide two regioisomers (4a) and (4a´). The single crystals of the product
were grown in pyridine and the structure was assigned by single crystal X-ray analysis as (4a) (Figure 1).
Plausible mechanism of the presented MCR involves the formation of the arylidene Meldrum´s acid (6)
(Scheme 3), which was detected in the reaction mixture by HPLC-MS. In the model experiment the
cyclocondensation of separately prepared (6) with pyrazole (1) delivered the same regioisomer (4a) as the
multicomponent protocol and the yield for both procedures was almost identical. In the next step, Michael
addition of the exocyclic amino group to β-carbon of compound (6) led to the intermediate (7), which
underwent cyclisation with simultaneous elimination of an acetone and carbon dioxide molecule (path A).
Alternatively, the first step of the plausible mechanism can be reversible formation of imine (8), path B.
However, in the model experiment, aldehyde (3a) and pyrazole (1) gave only a low amount of imine (8),
less then 10%. Moreover, imine (8) was not detected in the MCR, therefore pathway B can be excluded.
Scheme 3. Proposed mechanism of the MCR
The scope of the optimized MCR with various benzaldehydes (3a-q) was extended to the synthesis of
seventeen pyrazolopyrimidines (4a-q) [Table 2 (reaction shown in Scheme 1)]. All compounds were
isolated by simple filtration as single regioisomers in high isolated yields, 79 – 92%. Moreover, the purity
1
of the crude products exceeded 95%, as determined by a combination of H NMR and HPLC-MS. The
crystallization from EtOH afforded analytically pure samples. All substituents on aldehydes (3a-q) (CF3,
NO2, OMe, OH, F, Cl) were compatible with the reaction. Any significant effect of electron donating or
electron withdrawing groups on the reaction rate and yield was not observed. It can be expected, that the
dihydropyrazolopyrimidine could be prone to aromatization (oxidation). However, any decomposition or

HETEROCYCLES, Vol. 89, No. 8, 2014
1897
aromatization of (4a) was not detected even after six months standing at room temperature in solid state
or in DMF solution.
Table 2. The MCR synthesis of pyrazolopyrimidines (4a-q) using benzaldehydes (3a-q)
Entry
4a
R
Yielda (%)
Entry
4j
R
Yielda (%)
4-OMe
2-OMe
4-OH, 3-OMe
2,4-OMe
2,4,6-OMe
3-OH
86
83
89
85
87
92
80
88
90
4-F
86
82
92
91
87
80
84
79
4b
4c
4k
2-Cl, 6-F
2,6-Cl
2-CF3
4-CF3
3-CF3
2-NO2
4-NO2
4l
4d
4e
4m
4n
4f
4o
4g
2,6-Me
2-F
4p
4h
4i
4q
3-F
aIsolated yields of pyrazolopyrimidines (4a-q) after filtration (purity > 95%).
All prepared dihydropyrazolo[1,5-a]pyrimidines (4a-q) were assayed for their CDK inhibitory activity as
described.17 However, the results were negative probably due to structural differences from potent CDK
inhibitors based on pyrazolo[1,5-a]pyrimidines10b,c and 3,5-diaminopyrazoles (including CAN508).17
Although the acylation of the exocyclic aminopyrazole group enhanced CDK inhibition17b the formation
of partially saturated pyrimidine ring led to conformation where the aryl substituent was oriented more
axially with respect to pyrazolopyrimidine system.
In summary, an efficient, regioselective and high yielding MCR protocol for the synthesis of
dihydropyrazolo[1,5-a]pyrimidines was developed. The regioisomeric outcome of the presented MCR
was unambiguously proved by X-ray analysis. All compounds were obtained in high purity as stable
crystalline solids, thoroughly characterized and tested for CDK inhibitory activity. Unfortunately, they
did not show any significant CDK inhibitory potency probably due to their conformation.

1898
HETEROCYCLES, Vol. 89, No. 8, 2014
EXPERIMENTAL
All starting materials, solvents and reagents were purchased from commercial suppliers and were used as
received without further purification. Pyrazole (1) was prepared according the known procedure.17a
Melting points were determined on a Boetius stage. The HPLC-MS analyses were carried out on an
UHPLC-MS system consisting of an Accela UHPLC chromatograph with a photodiode array detector and
a TSQ Quantum Access triple quadrupole mass spectrometer (both Thermo Scientific, CA, USA), using a
Nucleodur Gravity C18 column (Macherey-Nagel, 1.8 μm, 2.1 x 50 mm, Germany) at 30 °C and a flow
rate of 800 μL/min. The APCI source operated at a discharge current of 5 μA, vaporizer temperature of
400 °C and capillary temperature of 200 °C. The 1H and 13C NMR spectra were recorded in DMSO-d6 at
20 °C on a Bruker 400 or 300 FT NMR spectrometer. Elemental analyses were performed using a Flash
2000 CHNS Elemental Analyzer (Thermo Scientific). X-Ray data of (4a) were collected on an
XcaliburTM2 diffractometer (Oxford Diffraction Ltd.) equipped with Sapphire2 CCD detector, with Mo
Kradiation (Monochromator Enhance, Oxford Diffraction Ltd.), and at 120 K. Software used for data
collection, data reduction, structure solution and refinement, together with crystal data and structure
refinement, selected bond lengths and angles, and hydrogen bonds, are given in Supplementary data.
Representative procedure for the synthesis of dihydropyrazolo[1,5-a]pyrimidines (4a-q).
A mixture of aminopyrazole (1) (0.22 g, 1.0 mmol), Meldrum´s acid (2) (0.16 g, 1.1 mmol,) and
4-methoxybenzaldehyde (0.15 g, 1.1 mmol) was stirred in boiling EtOH (4 mL) for 16 h. After the
mixture was cooled to a room temperature, the orange solid was collected by filtration, washed with cold
EtOH and dried under vacuum to yield pyrazolopyrimidine (4a) as an orange solid (0.33 g, 86%).
2-Amino-3-[(E)-(4-hydroxyphenyl)diazenyl]-5-(4-methoxyphenyl)-5,6-dihydropyrazolo[1,5-a]pyri-
1
midin-7(4H)-one (4a): orange solid 0.33 g (86%), mp 280-282 °C (EtOH); H NMR (400 MHz,
DMSO-d6)  ppm 2.98 (dd, J = 16.4, 7.8 Hz, 1 H), 3.08 (dd, J = 16.4, 5.7 Hz, 1 H), 3.74 (s, 3 H), 5.00 (dd,
J = 7.8, 5.7 Hz, 1 H), 6.28 (br. s, 2 H), 6.80 (d, J = 8.8 Hz, 2 H), 6.96 (d, J = 8.6 Hz, 2 H), 7.33 (d, J = 8.6 Hz,
13
2 H), 7.67 (d, J = 8.8 Hz, 2 H), 8.74 (br. s, 1 H), 9.78 (br. s, 1 H); C NMR (101 MHz, DMSO-d6)  ppm
39.2, 53.3, 55.2, 112.0, 114.1, 115.4, 122.8, 127.6, 132.4, 145.9, 146.0, 153.4, 158.2, 159.0, 160.4.
Anal.Calcd for C19H18N6O3 (378.14); C, 60.31; H, 4.79; N, 22.21. Found: C, 60.24; H, 4.90; N, 22.34.
2-Amino-3-[(E)-(4-hydroxyphenyl)diazenyl]-5-(2-methoxyphenyl)-5,6-dihydropyrazolo[1,5-a]-
pyrimidin-7(4H)-one (4b): Prepared according to the representative procedure using aldehyde (3b).
Yellow solid 0.31 g (83%), mp 268-270 °C (EtOH); 1H NMR (300 MHz, DMSO-d6)  ppm 2.87 (dd, J =
16.6, 5.5 Hz, 1 H), 3.25 (dd, J = 16.6, 6.4 Hz, 1 H), 3.85 (s, 3 H), 5.23 (t, J = 5.6 Hz, 1 H), 6.26 (br. s, 2 H),
6.82 (d, J = 8.7 Hz, 2 H), 6.96 (t, J = 7.3 Hz, 1 H), 7.07 (d, J = 8.2 Hz, 1 H), 7.16 (d, J = 7.3 Hz, 1 H), 7.3 (t,
J = 7.3 Hz, 1 H), 7.68 (d, J = 8.7 Hz, 2 H), 8.72 (br. s, 1 H), 9.80 (br. s, 1 H); 13C NMR (75 MHz, DMSO-d6)

HETEROCYCLES, Vol. 89, No. 8, 2014
1899
 ppm 36.9, 48.8, 55.6, 111.3, 111.9, 115.5, 120.6, 122.7, 125.9, 128.0, 129.3, 145.0, 146.0, 154.0, 156.1,
158.2, 160.3. Anal.Calcd for C19H18N6O3 (378.14); C, 60.31; H, 4.79; N, 22.21. Found: C, 60.53; H, 4.56;
N, 22.01.
2-Amino-5-(4-hydroxy-3-methoxyphenyl)-3-[(E)-(4-hydroxyphenyl)diazenyl]-5,6-dihydropyrazolo-
[1,5-a]pyrimidin-7(4H)-one (4c): Prepared according to the representative procedure using aldehyde
(3c).Yellow solid 0.35 g (89%), mp 284-285 °C (EtOH); 1H NMR (300 MHz, DMSO-d6)  ppm 3.00 (dd, J
= 17.0, 5.7 Hz, 1 H), 3.09 (dd, J = 17.0, 8.4 Hz, 1 H), 3.77 (s, 3 H), 4.96 (t, J = 6.7 Hz, 1 H), 6.31 (br. s, 2 H),
6.74 - 6.88 (m, 4 H), 7.05 (s, 1 H), 7.70 (d, J = 8.4 Hz, 2 H), 8.93 (br. s, 1 H), 9.77 (br. s, 1 H); 13C NMR (75
MHz, DMSO-d6)  ppm 39.4, 53.9, 55.7, 111.0, 112.0, 115.4, 115.5, 118.7, 122.9, 131.1, 146.1, 146.2,
146.5, 147.7, 153.4, 158.2, 160.6. Anal.Calcd for C19H18N6O4 (394.38); C, 57.86; H, 4,60; N, 21.31. Found:
C, 57.66; H, 4.82; N, 21.05.
2-Amino-5-(2,4-dimethoxyphenyl)-3-[(E)-(4-hydroxyphenyl)diazenyl]-5,6-dihydropyrazolo[1,5-a]-
pyrimidin-7(4H)-one (4d): Prepared according to the representative procedure using aldehyde (3d).
1
Yellow solid 0.34 g (85%), mp 276-278 °C (EtOH); H NMR (300 MHz, DMSO-d6)  ppm 2.89 (dd, J =
16.5, 5.5 Hz, 1 H), 3.15 - 3.23 (m, 1 H), 3.74 (s, 3 H), 3.83 (s, 3 H), 5.17 (t, J = 5.3 Hz, 1 H), 6.27 (br. s, 2 H),
6.53 (d, J = 8.1 Hz, 1 H), 6.62 (s, 1 H), 6.84 (d, J = 8.1 Hz, 2 H), 7.09 (d, J = 8.1 Hz, 1 H), 7.69 (d, J = 8.1
13
Hz, 2 H), 8.69 (br. s, 1 H), 9.79 (br. s, 1 H); C NMR (75 MHz, DMSO-d6)  ppm 37.2, 48.7, 55.3, 55.7,
98.9, 104.8, 112.0, 115.5, 120.2, 122.8, 126.8, 145.1, 146.1, 154.0, 157.3, 158.2, 160.5, 160.5. Anal.Calcd
for: C20H20N6O4 (408.41); C, 58.82; H, 4.94; N, 20.58. Found: C, 58,63; H, 4.86; N, 20.74.
2-Amino-5-(2,4,6-trimethoxyphenyl)-3-[(E)-(4-hydroxyphenyl)diazenyl]-5,6-dihydropyrazolo-
[1,5-a]-pyrimidin-7(4H)-one (4e): Prepared according to the representative procedure using aldehyde (3e).
1
Yellow solid 0.38 g (87%), mp 295-296 °C (EtOH); H NMR (300 MHz, DMSO-d6)  ppm 2.88 (dd, J =
16.8, 5.3 Hz, 1 H), 3.12 (dd, J = 16.8, 8.1 Hz, 1 H), 3.72 (s, 6 H), 3.77 (s, 3 H), 5.49 (dd, J = 8.1, 5.3 Hz, 1
H), 6.20 (br. s, 2 H), 6.25 (s, 2 H), 6.78 (d, J = 8.6 Hz, 2 H), 7.61 (d, J = 8.6 Hz, 2 H); 13C NMR (75 MHz,
DMSO-d6)  ppm 35.7, 44.3, 54.1, 55.5, 91.3, 109.0, 111.5, 115.3, 122.5, 146.1, 146.5, 152.7, 157.7, 158.9,
160.5, 160.9. Anal.Calcd for C21H22N6O5 (438.44); C, 57.53; H, 5.06; N, 19.17. Found: C, 57.42; H, 5.18;
N, 18.91.
2-Amino-5-(3-hydroxyphenyl)-3-[(E)-(4-hydroxyphenyl)diazenyl]-5,6-dihydropyrazolo[1,5-a]-
pyrimidin-7(4H)-one (4f): Prepared according to the representative procedure using aldehyde (3f).
Yellow solid 0.33 g (92%), mp 312-314 °C (EtOH); 1H NMR (300 MHz, DMSO-d6)  ppm 2.92 (dd, J =
16.6, 7.0 Hz, 1 H), 3.16 (dd, J = 16.6, 5.7 Hz, 1 H), 4.98 (t, J = 6.1 Hz, 1 H), 6.30 (br. s, 2 H), 6.72 (d, J = 7.9
Hz, 1 H), 6.76 - 6.87 (m, 4 H), 7.18 (t, J = 7.8 Hz, 1 H), 7.69 (d, J = 8.6 Hz, 2 H), 9.55 (br. s, 1 H), 9.78 (br.
s, 1 H). 13C NMR (75 MHz, DMSO-d6)  ppm 39.1, 53.6, 111.9, 112.9, 114.8, 115.4, 116.8, 122.8, 129.8,

1900
HETEROCYCLES, Vol. 89, No. 8, 2014
142.2, 145.6, 146.1, 153.6, 157.6, 158.2, 160.3. Anal.Calcd for C18H16N6O3 (364.36); C, 59.34; H, 4.43; N,
23.07. Found: C, 59.30; 4.47; N, 22.78.
2-Amino-5-(2,6-dimethylphenyl)-3-[(E)-(4-hydroxyphenyl)diazenyl]-5,6-dihydropyrazolo[1,5-a]-
pyrimidin-7(4H)-one (4g): Prepared according to the representative procedure using aldehyde (3g).
1
Yellow solid 0.30 g (80%), mp 298-300 °C (EtOH); H NMR (300 MHz, DMSO-d6)  ppm 2.45 (s, 6 H),
2.75 (dd, J = 16.9, 4.9 Hz, 1 H), 3.22 (dd, J = 16.9, 14.3 Hz, 1 H), 5.52 (dd, J = 14.3, 4.9 Hz, 1 H), 6.32 (br.
s, 2 H), 6.78 (d, J = 8.6 Hz, 2 H), 7.06 (d, J = 7.0 Hz, 2 H), 7.13 (dd, J = 8.4, 6.4 Hz, 1 H), 7.64 (d, J = 8.6 Hz,
2 H), 8.64 (br. s, 1 H), 9.69 (br. s, 1 H). 13C NMR (75 MHz, DMSO-d6)  ppm 20.7, 35.3, 50.9, 112.1, 115.3,
122.6, 127.6, 129.4, 134.7, 136.7, 145.9, 147.5, 152.6, 157.9, 160.5. Anal.Calcd for C20H20N6O2 (376.41);
C, 63.82; H, 5.36; N, 22.33. Found:C, 63.41; H, 5.34; N, 22.21.
2-Amino-5-(2-fluorophenyl)-3-[(E)-(4-hydroxyphenyl)diazenyl]-5,6-dihydropyrazolo[1,5-a]-
pyrimidin-7(4H)-one (4h): Prepared according to the representative procedure using aldehyde (3h).
1
Yellow solid 0.32 g (88%), mp 288-290 °C (EtOH); H NMR (300 MHz, DMSO-d6)  ppm 2.95 (dd, J =
16.6, 7.7 Hz, 1 H), 3.19 (dd, J = 16.6, 5.9 Hz, 1 H), 5.33 (t, J = 6.7 Hz, 1 H), 6.31 (br. s, 2 H), 6.82 (d, J = 8.6
Hz, 2 H), 7.20 - 7.32 (m, 2 H), 7.35 - 7.47 (m, 2 H), 7.68 (d, J = 8.6 Hz, 2 H), 8.80 (br. s, 1 H), 9.79 (br. s, 1
H); 13C NMR (75 MHz, DMSO-d6)  ppm 37.7, 48.2 (d, 3JCF = 3.3 Hz), 112.1, 115.4, 115.7 (d, 2JCF = 22.1
Hz), 122.8, 124.8 (d, 4JCF = 3.3 Hz), 127.4 (d, 2JCF = 13.3 Hz), 127.7 (d, 3JCF = 3.3 Hz), 130.0 (d, 3JCF = 7.7
Hz), 145.8, 145.9, 153.4, 158.2, 159.8, 160.0 (d, 1JCF = 245.5 Hz). Anal.Calcd for C18H15FN6O2 (366.35); C,
59.01; H, 4.13; N, 22.94. Found: C, 58.83; H, 4.03; N, 22.47.
2-Amino-5-(3-fluorophenyl)-3-[(E)-(4-hydroxyphenyl)diazenyl]-5,6-dihydropyrazolo[1,5-a]-
pyrimidin-7(4H)-one (4i): Prepared according to the representative procedure using aldehyde (3i). Yellow
solid 0.33 g (90%), mp 270-272 °C (EtOH); 1H NMR (300 MHz, DMSO-d6)  ppm 3.04 (dd, J = 16.8, 7.9
Hz, 1 H), 3.14 (dd, J = 16.8, 5.7 Hz, 1 H), 5.09 (t, J = 6.6 Hz, 1 H), 6.29 (br. s, 2 H), 6.82 (d,J = 8.6 Hz, 2 H),
7.17 (t, J = 8.4 Hz, 1 H), 7.22 - 7.33 (m, 2 H), 7.40 - 7.52 (m, 1 H), 7.69 (d, J = 8.6 Hz, 2 H), 8.82 (br. s, 1 H),
9.78 (br. s, 1 H); 13C NMR (75 MHz, DMSO-d6)  ppm 38.9, 53.4, 112.0, 113.4 (d, 2JCF = 22.1 Hz), 114.8
(d, 2JCF = 21.0 Hz), 115.4, 122.4 (d,4JCF = 3.3 Hz), 122.8, 130.7 (d, 3JCF = 8.9 Hz), 143.5 (d, 3JCF = 6.6 Hz),
1
145.8, 145.9, 153.3, 158.2, 160.1, 162.9 (d, JCF = 244.4 Hz). Anal.Calcd for C18H15FN6O2 (366.35); C,
59.01; H, 4.13; N, 22.94. Found: C, 58.82; 3.98; N, 23.37.
2-Amino-5-(4-fluorophenyl)-3-[(E)-(4-hydroxyphenyl)diazenyl]-5,6-dihydropyrazolo[1,5-a]pyrimi-
din-7(4H)-one (4j): Prepared according to the representative procedure using aldehyde (3j). Yellow solid
0.31 g (86%), mp 286-288 °C (EtOH); 1H NMR (300 MHz, DMSO-d6)  ppm 3.01 (dd, J = 16.7, 8.1 Hz, 1
H), 3.10 (dd, J = 16.7, 5.9 Hz, 1 H), 5.07 (t, J = 6.7 Hz, 1 H), 6.28 (br. s, 2 H), 6.81 (d, J = 8.6 Hz, 2 H), 7.24
(t, J = 8.8 Hz, 2 H), 7.47 (dd, J = 8.1, 5.7 Hz, 2 H), 7.68 (d, J = 8.6 Hz, 2 H), 8.78 (br. s, 1 H), 9.77 (br. s, 1

HETEROCYCLES, Vol. 89, No. 8, 2014
1901
H); 13C NMR (75 MHz, DMSO-d6)  ppm 39.1, 53.2, 112.0, 115.3, 115.4 (d, 2JCF = 21.0 Hz), 122.8, 128.6
(d, 3JCF = 8.9 Hz), 136.7 (d, 4JCF = 3.3 Hz), 145.8, 145.9, 153.3, 158.2, 160.1, 161.2 (d, 1JCF = 244.4 Hz).
Anal.Calcd for C18H15FN6O2 (366.35); C, 59.01; H, 4.13; N, 22.94. Found: C, 58.69; H, 4.11; N, 22.73.
2-Amino-5-(2-chloro-6-fluorophenyl)-3-[(E)-(4-hydroxyphenyl)diazenyl]-5,6-dihydropyrazolo-
[1,5-a]pyrimidin-7(4H)-one (4k): Prepared according to the representative procedure using aldehyde (3k).
Orange solid 0.33 g (82%), mp 295-297 °C (EtOH); 1H NMR (300 MHz, DMSO-d6)  ppm 3.12 (d, J = 8.0
Hz, 2 H), 5.64 (t, J = 8.0 Hz, 1 H), 6.32 (br. s, 2 H), 6.80 (d, J = 8.4 Hz, 2 H), 7.19 - 7.35 (m, 1 H), 7.36 - 7.51
(m, 2 H), 7.64 (d, J = 8.4 Hz, 2 H), 8.86 (br. s, 1 H), 9.74 (br. s, 1 H); 13C NMR (75 MHz, DMSO-d6)  ppm
35.3, 48.7, 112.0, 115.4, 115.8 (d, 2JCF = 23.2), 122.6, 125.0 (d, 2JCF = 14.4), 126.2 (d, 4JCF = 3.3 Hz), 130.8
3
3
1
(d, JCF = 11.1 Hz), 133.6 (d, JCF = 5.5 Hz), 145.8, 146.6, 152.8, 158.1, 159.6, 161.5 (d, JCF = 251.0).
Anal.Calcd for C18H14ClFN6O2 (400.79); C, 53.94; H, 3.52; N, 20.97. Found: C, 53.69; H, 3.74; N, 20.62.
2-Amino-5-(2,6-dichlorophenyl)-3-[(E)-(4-hydroxyphenyl)diazenyl]-5,6-dihydropyrazolo[1,5-a]-
pyrimidin-7(4H)-one (4l): Prepared according to the representative procedure using aldehyde (3l). Red
1
solid 0.38 g (92%), mp 302-304 °C (EtOH); H NMR (400 MHz, DMSO-d6) 2.93 (dd, J = 17.0, 6.5 Hz, 1
H), 3.34 (dd,J = 17.0, 11.9 Hz, 1 H), 5.92 (dd, J = 11.9, 6.5 Hz, 1 H), 6.38 (br. s, 2 H), 6.79 (d, J = 8.6 Hz,
13
2 H), 7.41 (t, J = 7.9 Hz, 1 H), 7.55 (d, J = 7.9 Hz, 2 H), 7.63 (d, J = 8.6 Hz, 2 H); C NMR (101 MHz,
DMSO-d6)  ppm 34.1, 51.0, 112.3, 115.4, 122.5, 129.9, 130.6, 133.6, 134.7, 145.6, 147.1, 152.7, 158.0,
159.4. Anal.Calcd for C18H14Cl2N6O2 (417.25); C, 51.81; H, 3.38; N, 20.14. Found: C, 51.46; H, 3.23; N,
20.18.
2-Amino-3-[(E)-(4-hydroxyphenyl)diazenyl]-5-[2-(trifluoromethyl)phenyl]-5,6-dihydropyrazolo[1,5-
a]pyrimidin-7(4H)-one (4m):Prepared according to the representative procedure using aldehyde (3m).
1
Yellow solid 0.38 g (91%), mp 289-291 °C (EtOH); H NMR (400 MHz, DMSO-d6)  ppm 2.95 (dd, J =
16.5, 5.5 Hz, 1 H), 3.05 (dd, J = 16.5, 9.8 Hz, 1 H), 5.36 (dd, J = 9.8, 5.5 Hz, 1 H), 6.36 (br. s, 2 H), 6.80 (d,
J = 8.6 Hz, 2 H), 7.59 (t, J = 7.7 Hz, 1 H), 7.66 (d, J = 8.6 Hz, 2 H), 7.73 - 7.83 (m, 2 H), 7.92 (d, J = 7.7 Hz,
13
1 H), 8.82 (br. s, 1 H), 9.77 (br. s, 1 H); C NMR (101 MHz, DMSO-d6)  ppm 39.6, 50.8, 112.1, 115.4,
122.9, 124.1 (q, 1JCF = 274.0 Hz), 125.8 (q, 3JCF = 5.5 Hz), 126.2 (q, 2JCF = 29.9 Hz), 128.6, 128.7, 133.3,
139.4, 145.9, 147.4, 152.8, 158.3, 159.5. Anal.Calcd for C19H15F3N6O2 (416.36); C, 54.81; H, 3.36; N,
20.18. Found: C, 54.61; H, 3.58; N, 19.96.
2-Amino-3-[(E)-(4-hydroxyphenyl)diazenyl]-5-[4-(trifluoromethyl)phenyl]-5,6-dihydropyrazolo[1,5-
a]pyrimidin-7(4H)-one (4n): Prepared according to the representative procedure using aldehyde (3n).
1
Yellow solid 0.36 g (87%), mp 283-285 °C (EtOH); H NMR (300 MHz, DMSO-d6)  ppm 3.04 (dd, J =
16.6, 8.2 Hz, 1 H), 3.17 (dd, J = 16.6, 5.7 Hz, 1 H), 5.18 (t, J = 6.6 Hz, 1 H), 6.31 (br. s, 2 H), 6.81 (d, J = 8.6
13
Hz, 2 H), 7.60 - 7.73 (m, 4 H), 7.79 (d, J = 8.2 Hz, 2 H), 8.86 (br. s, 1 H), 9.79 (br. s, 1 H); C NMR (75

1902
HETEROCYCLES, Vol. 89, No. 8, 2014
MHz, DMSO-d6)  ppm 38.8, 53.6, 112.1, 115.4, 122.9, 124.2 (q, 1JCF= 272.5 Hz), 125.6 (q, 3JCF = 3.8 Hz),
127.39, 127.40, 128.47 (q, 2JCF = 31.9 Hz), 145.4, 145.9, 153.4, 158.3, 160.0. Anal.Calcd for C19H15F3N6O2
(416.36); C, 54.81; H, 3.36; N, 20.18. Found: C, 54.62; H, 3.55; N, 20.23.
2-Amino-3-[(E)-(4-hydroxyphenyl)diazenyl]-5-[3-(trifluoromethyl)phenyl]-5,6-dihydropyrazolo[1,5-
a]pyrimidin-7(4H)-one (4o): Prepared according to the representative procedure using aldehyde (3o).
Orange solid 0.33 g (80%), mp 274-276 °C (EtOH); 1H NMR (300 MHz, DMSO-d6)  ppm 3.11 (d, J = 6.9
Hz, 2 H), 5.19 (t, J = 6.9 Hz, 1 H), 6.33 (br. s, 2 H), 6.81 (d, J = 8.6 Hz, 2 H), 7.60 – 7.80 (m, 3 H), 7.68 (d,
13
J = 8.6 Hz, 2 H), 7.84 (s., 1 H), 8.83 (br. s, 1 H), 9.80 (br. s, 1 H); C NMR (75 MHz, DMSO-d6)  ppm
(one signal overlap by DMSO), 53.7, 112.1, 115.4, 122.9, 123.6 (q, 1JCF = 3.9 Hz), 124.3 (q, 1JCF = 272.5
3
2
Hz), 124.8 (q, JCF = 3.1 Hz), 129.3 (q, JCF = 31.9 Hz), 129.9, 130.7, 142.0, 145.9, 146.4, 153.2, 158.3,
160.1. Anal.Calcd for C19H15F3N6O2 (416.36); C, 54.81; H, 3.36; N, 20.18. Found: C, 54.51; H, 3.64; N,
20.24.
2-Amino-3-[(E)-(4-hydroxyphenyl)diazenyl]-5-(2-nitrophenyl)-5,6-dihydropyrazolo[1,5-a]pyrimi-
din-7(4H)-one (4p): Prepared according to the representative procedure using aldehyde (3p). Orange solid
1
0.33 g (84%), mp 278-280 °C (EtOH); H NMR (300 MHz, DMSO-d6)  ppm 3.05 (dd, J=16.6, 8.8 Hz, 1
H), 3.28 (dd, J = 16.6, 5.7 Hz, 1 H), 5.49 (dd, J = 8.8, 5.7 Hz, 1 H), 6.32 (br. s, 2 H), 6.81 (d, J = 8.6 Hz, 2
H), 7.56 - 7.71 (m, 3 H), 7.74 - 7.84 (m, 2 H), 8.04 (d, J = 7.9 Hz, 1 H), 8.73 (br. s, 1 H), 9.79 (br.s, 1 H); 13C
NMR (75 MHz, DMSO-d6)  ppm 38.2, 50.2, 112.4, 115.4, 122.7, 124.7, 128.4, 129.4, 134.1, 135.4, 145.4,
145.6, 148.2, 153.8, 158.3, 159.5. Anal.Calcd for C18H15N7O4 (393.36); C, 54.96; H, 3.84; N, 24.93. Found:
C, 54.61; H, 3.83; N, 24.74.
2-Amino-3-[(E)-(4-hydroxyphenyl)diazenyl]-5-(4-nitrophenyl)-5,6-dihydropyrazolo[1,5-a]pyrimi-
din-7(4H)-one (4q): Prepared according to the representative procedure using aldehyde (3q). Orange solid
0.31 g (79%), mp 332-334 °C (EtOH); 1H NMR (300 MHz, DMSO-d6)  ppm 3.03 (dd, J = 16.5, 7.9 Hz, 1
H), 3.19 (dd, J=16.5, 5.8 Hz, 1 H), 5.24 (dd, J = 7.9, 5.8 Hz, 1 H), 6.30 (br. s, 2 H), 6.82 (d, J = 8.6 Hz, 2 H),
7.68 (d, J = 7.8 Hz, 2 H), 7.71 (d, J = 7.8 Hz, 2 H), 8.28 (d, J = 8.6 Hz, 2 H), 8.91 (br. s, 1 H), 9.80 (br. s, 1
H). 13C NMR (75 MHz, DMSO-d6)  ppm (one signal overlap by DMSO) 53.4, 112.2, 115.4, 122.8, 123.8,
127.8, 145.6, 145.8, 147.1, 148.2, 153.4, 158.3, 159.8. Anal.Calcd for C18H15N7O4 (393.36); C, 54.96; H,
3.84; N, 24.93. Found: C, 55.51; H, 3.74; N, 25.17.
ACKNOWLEDGEMENTS
The authors acknowledge financial support from the Operational Program Education for Competitiveness
(CZ.1.07/2.4.00/31.0130, CZ.1.07/2.3.00/20.0009 and CZ.1.07/2.3.00/20.0017), the Operational Program
Research and Development for Innovations (CZ.1.05/2.1.00/03.0058), and IGA (Prf2012 027 and

HETEROCYCLES, Vol. 89, No. 8, 2014
1903
Prf2013 036).
REFERENCES
1. (a) K. Senga, T. Novinson, R. H. Springer, R. P. Rao, D. E. O´Brien, R. K. Robins, and H. R. Wilson,
J. Med. Chem., 1975, 18, 312; (b) T. Novinson, J. P. Miller, M. Scholten, R. K. Robins, L. N. Simon,
D. E. O´Brien, and R. B. Meyer, Jr., J. Med. Chem., 1975, 18, 460.
2. R. H. Springer, M. B. Scholten, D. E. O´Brien, T. Novinson, J. P. Miller, and R. K. Robins, J. Med.
Chem., 1982, 25, 235.
3. G. Almansa, A. F. Arriba, F. L. Cavalcanti, L. A. Gomez, A. Miralles, M. Merlos, J. Garcia-Rafanell,
and J. Forn, J. Med. Chem., 2001, 44, 350.
4. S. Selleri, F. Bruni, C. Costagli, A. Costanzo, G. Guerrini, G. Ciciani, P. Gratteri, C. Bonaccini, P. M.
Aiello, F. Besnard, S. Renard, B. Costa, and C. Martini, J. Med. Chem., 2003, 46, 310.
5. (a) C. Chen, K. M.Wilcoxen, C. Q. Huang, Y. F. Xie, J. R. McCarthy, T. R. Webb, Y. F. Zhu, J.
Saunders, X. J. Liu, T. K. Chen, H. Bozigian, and D. E. Grigoriadis, J. Med. Chem., 2004, 47, 4787;
(b) P. J. Gilligan, C. Baldauf, A. Cocuzza, D. Chidester, R. Zaczek, L. W. Fitzgerald, J. McElroy, M.
A. Smith, H. L. Shen, J. A. Saye, D. Christ, G. Trainor, D. W. Robertson, and P. Hartig, Bioorg. Med.
Chem., 2000, 8, 181.
6. D. R. Compton, S. Sheng, K. E. Carlson, N. A. Rebacz, I. Y. Lee, B. S. Katzenellenbogen, and J. A.
Katzenellenbogen, J. Med. Chem., 2004, 47, 5872.
7. (a) H. Mukaiyama, T. Nishimura, S. Kobayashi, Y. Komatsu, S. Kikuchi, T. Ozawa, N. Kamada,
and H. Ohnota, Bioorg. Med. Chem., 2008, 16, 909; (b) H. Mukaiyama, T. Nishimura, H. Shiohara, S.
Kobayashi, Y. Komatsu, S. Kikuchi, E. Tsuji, N. Kamada, H. Ohnota, and H. Kusama, Chem. Pharm.
Bull., 2007, 55, 881.
8. E. J. Hanan, A. Abbema, K. Barrett, W. S. Blair, J. Blaney, C. Chang, C. Eigenbrot, S. Flynn, P.
Gibbons, C. A. Hurley, J. R. Kenny, J. Kulagowski, L. Lee, S. R. Magnuson, C. Morris, J. Murray, R.
M. Pastor, T. Rawson, M. Siu, M. Ultsch, A. Zhou, D. Sampath, and J. P. Lyssikatos, J. Med. Chem.,
2012, 55, 10090.
9. H. Yu, M. L. Moore, K. Erhard, M. A. Hardwicke, H. Lin, J. I. Luengo, J. McSurdy-Freed, R. Plant,
J. Qu, K. Raha, C. M. Rominger, M. D. Schaber, M. D. Spengler, and R. A. Rivero, Med. Chem.
Lett., 2013, 4, 230.
10. (a) D. A. Heathcote, H. Patel, S. H. B. Kroll, P. Hazel, M. Periyasamy, M. Alikian, S. K. Kanneganti,
A. S. Jogalekar, B. Scheiper, M. Barbazanges, A. Blum, J. Brackow, A. Siwicka, R. D. M. Pace, M.
J. Fuchter, J. P. Snyder, D. C. Liotta, P. S. Freemont, E. O. Aboagye, C. Coombes, A. G. M. Barrett,
and S. Ali, J. Med. Chem., 2010, 53, 8508; (b) M. P. Dwyer, K. Paruch, C. Alvarez, R. J. Doll, K.

1904
HETEROCYCLES, Vol. 89, No. 8, 2014
Keertikar, J. Duca, T. O. Fischmann, A. Hruza, V. Madison, E. Lees, D. Parry, W. Seghezzi, N.
Sgambellone, F. Shanahan, D. Wiswellb, and T. J. Guzi, Bioorg. Med. Chem. Lett., 2007, 17, 6216;
(c) K. Paruch, M. P. Dwyer, C. Alvarez, C. Brown, T. Y. Chan, R. J. Doll, K. Keertikar, C. Knutson,
B. McKittrick, J. Rivera, R. Rossman, G. Tucker, T. O. Fischmann, A. Hruza, V. Madison, A. A.
Nomeir, Y. Wang, E. Lees, D. Parry, N. Sgambellone, W. Seghezzi, L. Schultz, F. Shanahan, D.
Wiswell, X. Xu, Q. Zhou, R. A. James, V. M. Paradkar, H. Park, L. R. Rokosz, T. M. Staufferc, and
T. J. Guzi, Bioorg. Med. Chem. Lett., 2007, 17, 6220.
11. (a) J. Lloyd, H. J. Finlay, W. Vacarro, T. Hyunh, A. Kover, R. Bhandaru, L. Yan, K. Atwal, M. L.
Conder, T. Jenkins-West, H. Shi, C. Huang, D. Li, H. Sun, and P. Levesque, Bioorg. Med. Chem.
Lett., 2010, 20, 1436; (b) H. J. Finlay, J. Lloyd, W. Vaccaro, A. Kover, L. Yan, G. Bhave, J. Prol, T.
Huynh, R. Bhandaru, Y. Caringal, J. DiMarco, J. Gan, T. Harper, C. Huang, M. L. Conder, H. Sun, P.
Levesque, M. Blanar, K. Atwal, and R. Wexler, J. Med. Chem., 2012, 55, 3036.
12. (a) X. Q. Deng, L. N. Quan, M. X. Song, C. X. Wei, and Z. S. Quan, Eur. J. Med. Chem., 2011, 46,
2955; (b) V. V. Lipson, S. M. Desenko, M. G. Shirobokova, O. V. Shishkin, and S. V.Shishkina,
Russ. J. Org. Chem., 2006, 42, 1022; (c) S. M. Desenko, V. V. Lipson, O. V. Shishkin, S. A.
Komykhov, V. D. Orlov, E. E. Lakin, V. P. Kuznetsov, and H. Meier, J. Heterocycl. Chem., 1999, 36,
205.
13. (a) J. Lloyd, H. J. Finlay, K. Atwal, A. Kover, J. Prol, L. Yan, R. Bhandaru, W. Vaccaro, T. Huynh,
C. S. Huang, M. Conder, T. Jenkins-West, H. Sun, D. Li, and P. Levesque, Bioorg. Med. Chem. Lett.,
2009, 19, 5469; (b) W. Vaccaro, T. Huynh, J. Lloyd, K. Atwal, H. J. Finlay, P. Levesque, M. L.
Conder, T. Jenkins-West, H. Shi, and L. Sun, Bioorg. Med. Chem. Lett., 2008, 18, 6381.
14. (a) R. W. Armstrong, A. P. Combs, P. A. Tempest, S. D. Brown, and T. A. Keating, Acc. Chem. Res.,
1996, 29, 123; (b) J. Zhu, Eur. J. Org. Chem., 2003, 1133; (c) L. G. Voskressensky, A. A. Festa, and
A. V. Varlamov, Tetrahedron, 2014, 70, 551; (d) H. Eckert, Molecules, 2012, 17, 1074; (e) B. Jiang,
T. Rajale, W. Wever, S. J. Tu, and G. Li, Chem. Asian J., 2010, 5, 2318.
15. (a) V. V. Lipson and N. Y. Gorobets, Mol. Divers., 2009, 13, 399; (b) A. M. Dumasand and E.
Fillion, Acc. Chem. Res., 2010, 43, 440.
16. (a) P. Orsini, A. Maccario, and N. Colombo, Synthesis, 2007, 3185; (b) M. L. Deb, and P. J. Bhuyan,
Synth. Commun., 2006, 36, 3085; (c) S. Zhu, J. Wang, Z. Xu, and J. Li, Molecules, 2012, 17, 13856;
(d) B. Zou, C. Chen, S. Y. Leong, M. Ding, and P. W. Smith, Tetrahedron, 2014, 70, 578.
17. (a) V. Krystof, P. Cankar, I. Frysova, J. Slouka, G. Kontopidis, P. Dzubak, M. Hajduch, J. Srovnal,
W. F. Azevedo, Jr., M. Orsag, M. Paprskarova, J. Rolcik, A. Latr, P. M. Fischer, and M. Strnad, J.
Med. Chem., 2006, 49, 6500; (b) E. Schutznerova, I. Popa, V. Krystof, H. Koshino, Z. Travnicek, P.
Hradil, and P. Cankar, Tetrahedron, 2012, 68, 3996.